Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000593362 | SCV000708365 | uncertain significance | not provided | 2017-05-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001854097 | SCV002128525 | uncertain significance | Peroxisome biogenesis disorder, complementation group 7 | 2023-08-04 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The tryptophan amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 501854). This variant has not been reported in the literature in individuals affected with PEX10-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces serine, which is neutral and polar, with tryptophan, which is neutral and slightly polar, at codon 89 of the PEX10 protein (p.Ser89Trp). |
Prevention |
RCV004751622 | SCV005361149 | uncertain significance | PEX10-related disorder | 2024-09-11 | no assertion criteria provided | clinical testing | The PEX10 c.266C>G variant is predicted to result in the amino acid substitution p.Ser89Trp. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |